Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)

2. november 2026 opdateret af: Perceive Biotherapeutics, Inc.

Fase 1/2a dosiseskaleringsundersøgelse af VOY-101 hos patienter med avanceret ikke-neovaskulær aldersrelateret makuladegeneration

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study has a prospective, open-label, multi-center, two-part design to evaluate a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA), the advanced form of non-neovascular age-related macular degeneration (AMD). Phase 1 followed a standard dose escalation model to establish safety and tolerability of VOY-101 and determine the recommended phase 2 dose. This dose is being used in the randomized Phase 2 part of the study to evaluate the safety and efficacy of VOY-101 in the study eye compared to untreated fellow eye.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australien, 2000
        • Sydney Retina Clinic and Day Surgery
    • Victoria
      • East Melbourne, Victoria, Australien, 3002
        • Cerulea Clinical Trials
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85255
        • Retina Macula Institute of AZ
    • California
      • Poway, California, Forenede Stater, 92064
        • Retina Consultants San Diego
      • Sacramento, California, Forenede Stater, 95825
        • Retinal Consultants Medical Group
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Ophthalmic Consultants of Boston
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63128
        • The Retina Institute
    • New Jersey
      • Cherry Hill, New Jersey, Forenede Stater, 08034
        • Mid Atlantic Retina
    • Oregon
      • Portland, Oregon, Forenede Stater, 97221
        • Retina Northwest
    • South Dakota
      • Rapid City, South Dakota, Forenede Stater, 57701
        • Black Hills Regional Eye Institute
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Austin Research Center for Retina
      • Fort Worth, Texas, Forenede Stater, 76132
        • Star Retina
      • Southlake, Texas, Forenede Stater, 76092
        • Retina Center of Texas
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84132
        • University of Utah John A. Moran Eye Center
      • Haifa, Israel
        • Rambam Medical Center
      • Tel Aviv, Israel, 64239
        • Tel-Aviv Sourasky Medical Center, Ophthalmology Division

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Are ≥60 years of age at the time of consent.
  • Are willing and able to understand and provide written informed consent.
  • Are willing and able to return for scheduled treatment and follow-up examinations.
  • Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
  • Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
  • Absence of signs of non-exudative MNV.
  • Additional Ocular Inclusion Criteria for both eyes.
  • Meet certain genotype criteria for risk of AMD.

Exclusion Criteria:

  • Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
  • Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low

Single, unilateral, intravitreal injection of low dose of VOY-101

VOY-101

Eksperimentel: Medium

Single, unilateral, intravitreal injection of medium dose of VOY-101

VOY-101

Eksperimentel: High

Single, unilateral, intravitreal injection of high dose of VOY-101

VOY-101

Eksperimentel: Higher

Single, unilateral, intravitreal injection of higher dose of VOY-101

VOY-101

Eksperimentel: Intermediate

Single, unilateral, intravitreal injection of intermediate dose of VOY-101

VOY-101

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101
Tidsramme: 24 Months

Frequency and type of ocular and systemic adverse events and non-serious treatment-emergent adverse events

24 Months
Phase 1: Change from Baseline in markers of inflammation
Tidsramme: Baseline to Month 24

Change from Baseline in markers of inflammation including anterior chamber cells, vitreous cells, and retinal vasculitis and retinitis.

Baseline to Month 24
Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.
Tidsramme: Month 12

Determine whether the maximum tolerated dose (MTD) has been reached (as determined by the occurrence of dose-limiting toxicities [DLTs]) and select the RP2D.

Month 12
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.
Tidsramme: 15 Months

Change from Baseline in Geographic Atrophy lesion size

15 Months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors
Tidsramme: Baseline through 24 Months

Growth rate of total geographic atrophy lesion size and photoreceptor change

Baseline through 24 Months
Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101.
Tidsramme: Baseline through 24 Months

Change from Baseline for complement levels in aqueous humor

Baseline through 24 Months
Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity
Tidsramme: 24 Months

Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCDVA and Percentage of subjects with <15 letters lost in BCDVA from Treatment

24 Months
Phase 1/2: Development of macular neovascularization
Tidsramme: Month 24

Incidence, frequency, severity, and timing of development of macular neovascularization

Month 24
Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101
Tidsramme: 24 Months

Frequency of Investigational Product related ocular and systemic adverse events, adverse events of special interest and non-serious treatment-emergent adverse events.

24 Months
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy lesion size and photoreceptors
Tidsramme: Baseline through Month 24

Change in geographic atrophy lesion size and rate of photoreceptor loss

Baseline through Month 24
Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity
Tidsramme: Baseline through Month 24

Change from Baseline in the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual (LLVA) vision test

Baseline through Month 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Anne Fung, MD, Perceive Biotherapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. juni 2023

Primær færdiggørelse (Anslået)

1. oktober 2027

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

12. oktober 2023

Først indsendt, der opfyldte QC-kriterier

12. oktober 2023

Først opslået (Faktiske)

17. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PBI-AMD-002

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .